3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
PHASE2CompletedINTERVENTIONAL
Enrollment
48
Participants
Timeline
Start Date
July 31, 2005
Primary Completion Date
January 31, 2007
Conditions
Primary Peritoneal Cavity CancerRecurrent Ovarian Epithelial CancerStage III Ovarian Epithelial CancerStage IV Ovarian Epithelial Cancer
Interventions
DRUG
triapine
Given IV
DRUG
cisplatin
Given IV
OTHER
laboratory biomarker analysis
Correlative studies
Trial Locations (1)
19103
Gynecologic Oncology Group, Philadelphia
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00081276 - 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer | Biotech Hunter | Biotech Hunter